The Utility of Sulfonate Salts in Drug Development

被引:86
作者
Elder, David P. [2 ]
Delaney, Ed [3 ]
Teasdale, Andrew [4 ]
Eyley, Steve [4 ]
Reif, Van D. [5 ]
Jacq, Karine [1 ]
Facchine, Kevin L. [6 ]
Oestrich, Rolf Schulte [7 ]
Sandra, Patrick [1 ]
David, Frank [1 ]
机构
[1] Res Inst Chromatog, B-8500 Kortrijk, Belgium
[2] GlaxoSmithKline Res & Dev Ltd, Ware SG12 0DP, Herts, England
[3] React Sci Consulting LLC, Princeton, NJ 08540 USA
[4] Astra Zeneca, R&D Charnwood, Loughborough LE11 5RK, Leics, England
[5] Formerly Schering Plough, Summit, NJ 07901 USA
[6] GlaxoSmithKline Res & Dev Ltd, Res Triangle Pk, NC 27709 USA
[7] F Hoffmann La Roche & Co Ltd, CH-4070 Basel, Switzerland
关键词
alkylators; crystallinity; crystallization; formulation; hydrates/solvates; hygroscopicity; morphology; physicochemical properties; polymorphism; HYDROCHLORIDE SALTS; SOLUBILITY; SELECTION; DISSOLUTION; FORMS; PH; BIOAVAILABILITY; FORMULATIONS; STABILITY; CORROSION;
D O I
10.1002/jps.22058
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
The issue of controlling genotoxic impurities in novel active pharmaceutical ingredients (APIs) is a significant challenge. Much of the current regulatory concern, has been focused on the formation and control of genotoxic sulfonate esters. This is linked with the withdrawal of Viracept (Nefinavir mesilate) from European markets in mid-2007, over concerns about elevated levels of ethyl methanesulfonate (EMS). This issue has resulted in calls from European regulators to assess risk mitigation strategies for all marketed products employing a sulfonic acid counter-ion to ensure that the sulfonate esters that could be potentially formed are controlled to threshold of toxicological concern (TTC)-based limits. This has even led to calls to avoid sulfonic acids as salt counter-ions. However, sulfonic acid salts possess a range of properties that are useful to both synthetic and formulation chemists. Whilst sulfonate salts are not a universal panacea to some of the problems of salt formation they do offer significant advantages as alternatives to other salt forming moieties under certain circumstances. This review thus sets out to define some of the advantages provided through utilization of sulfonic acids, explaining the importance of their retention as part of a thorough salt selection process. (C) 2010 Wiley-Liss, Inc. and the American Pharmacists Association J Pharm Sci 99:2948-2961, 2010
引用
收藏
页码:2948 / 2961
页数:14
相关论文
共 63 条
  • [1] Role of water in the physical stability of solid dosage formulations
    Airaksinen, S
    Karjalainen, M
    Shevchenko, A
    Westermarck, S
    Leppänen, E
    Rantanen, J
    Yliruusi, J
    [J]. JOURNAL OF PHARMACEUTICAL SCIENCES, 2005, 94 (10) : 2147 - 2165
  • [2] A THEORETICAL BASIS FOR A BIOPHARMACEUTIC DRUG CLASSIFICATION - THE CORRELATION OF IN-VITRO DRUG PRODUCT DISSOLUTION AND IN-VIVO BIOAVAILABILITY
    AMIDON, GL
    LENNERNAS, H
    SHAH, VP
    CRISON, JR
    [J]. PHARMACEUTICAL RESEARCH, 1995, 12 (03) : 413 - 420
  • [3] [Anonymous], 1996, PRACTICE MED CHEM
  • [4] Pharmaceutical evaluation of early development candidates "the 100 mg-approach"
    Balbach, S
    Korn, C
    [J]. INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2004, 275 (1-2) : 1 - 12
  • [5] Salt selection and optimisation procedures for pharmaceutical new chemical entities
    Bastin, RJ
    Bowker, MJ
    Slater, BJ
    [J]. ORGANIC PROCESS RESEARCH & DEVELOPMENT, 2000, 4 (05) : 427 - 435
  • [6] BENNEKER FBD, 1998, 4 PHENYLPIPERIDINE C
  • [7] PHARMACEUTICAL SALTS
    BERGE, SM
    BIGHLEY, LD
    MONKHOUSE, DC
    [J]. JOURNAL OF PHARMACEUTICAL SCIENCES, 1977, 66 (01) : 1 - 19
  • [8] Bighley LD., 1996, ENCY PHARM TECHNOLOG, V13, P453
  • [9] Structure, solubility, screening, and synthesis of molecular salts
    Black, Simon N.
    Collier, Edwin A.
    Davey, Roger J.
    Roberts, Ron J.
    [J]. JOURNAL OF PHARMACEUTICAL SCIENCES, 2007, 96 (05) : 1053 - 1068
  • [10] Brittain HG, 2007, PHARM TECH, V31, P78